PACE-CME

Novel RNAi therapeutic lowers blood pressure in patients with hypertension

Novel RNAi therapeutic lowers blood pressure in patients with hypertension
RestartResume
3' education - Nov. 13, 2023 - George Bakris, MD
  • Overview

    AHA 2023 George Bakris shares the results of the KARDIA-1 trial, in which zilebesiran, a RNAi therapeutic targeting angiotensinogen, lowers blood pressure for up to 6 months with a single subcutaneous injection.

  • Educational information

    This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.

  • Faculty

    George L. Bakris, MD is Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine in Chicago, IL, USA.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the KARDIA-1 trial

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free